Fibrinolysis for intermediate-risk pulmonary embolism [2]

New England Journal of Medicine

Volumn 371, Issue 6, 2014, Pages 579-

  Girerd, Nicolas ^a   Rossignol, Patrick ^a   Zannad, Faiez ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLEEDING; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HUMAN; INCIDENCE; INTERMEDIATE RISK PATIENT; LETTER; LUNG EMBOLISM; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RISK ASSESSMENT; THERAPY EFFECT; TREATMENT INDICATION; TREATMENT RESPONSE; FEMALE; MALE; NOTE;

FIBRINOLYTIC AGENT; HEPARIN; TISSUE PLASMINOGEN ACTIVATOR;

FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; MALE; PULMONARY EMBOLISM; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84905727961     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1406283     Document Type: Letter

References (19)

1. G Meyer E Vicaut T Danays Fibrinolysis for patients with intermediate-risk pulmonary embolism N Engl J Med 370 2014 1402 1411
2. G Simoneau JF Bergmann A Kher C Soria G Tobelem Pharmacokinetics of a low molecular weight heparin [Fragmin] in young and elderly subjects Thromb Res 66 1992 603 607
3. DJ Quinlan A McQuillan JW Eikelboom Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials Ann Intern Med 140 2004 175 183
4. British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group British Thoracic Society guidelines for the management of suspected acute pulmonary embolism Thorax 58 2003 470 483
5. GF Genet SR Ostrowski AM Sorensen PI Johansson Detection of tPA-induced hyperfibrinolysis in whole blood by RapidTEG, KaolinTEG, and functional fibrinogenTEG in healthy individuals Clin Appl Thromb Hemost 18 2012 638 644
6. K Yamamoto K Takeshita T Kojima J Takamatsu H Saito Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly Cardiovasc Res 66 2005 276 285
7. P Angleton WL Chandler G Schmer Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1) Circulation 79 1989 101 106
8. HB Moore EE Moore E Gonzalez Hyperfibrinolysis, physiologic fibrinolysis, fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and the relevance to antifibrinolytic therapy J Trauma Acute Care Surg 2014 July 21 (Epub ahead of print).
9. MP Chapman EE Moore CR Ramos Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy J Trauma Acute Care Surg 75 2013 961 967
10. R Quiroz N Kucher UJ Schoepf Right ventricular enlargement on chest computed tomography: prognostic role in acute pulmonary embolism Circulation 109 2004 2401 2404
11. M Lankeit V Gomez C Wagner A strategy combining imaging and laboratory biomarkers in comparison with a simplified clinical score for risk stratification of patients with acute pulmonary embolism Chest 141 2012 916 922
12. V Pengo AW Lensing MH Prins Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism N Engl J Med 350 2004 2257 2264
13. JA Kline MT Steuerwald MR Marchick J Hernandez-Nino GA Rose Prospective evaluation of right ventricular function and functional status 6 months after acute submassive pulmonary embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure Chest 136 2009 1202 1210
14. S Fasullo S Scalzo G Maringhini Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin Am J Med Sci 341 2011 33 39
15. CG Elliott Fibrinolysis of pulmonary emboli — steer closer to Scylla N Engl J Med 370 2014 1457 1458
16. PW Armstrong AH Gershlick P Goldstein Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction N Engl J Med 368 2013 1379 1387
17. M Sharifi C Bay L Skrocki F Rahimi M Mehdipour Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” Trial) Am J Cardiol 111 2013 273 277
18. PW Armstrong AH Gershlick P Goldstein Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction N Engl J Med 368 2013 1379 1387
19. M Sharifi C Bay L Skrocki F Rahimi M Mehdipour Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” Trial) Am J Cardiol 111 2013 273 277